MARKET

FPRX

FPRX

Five Prime
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.330
-0.230
-8.98%
After Hours: 2.390 +0.06 +2.57% 16:45 03/27 EDT
OPEN
2.460
PREV CLOSE
2.560
HIGH
2.510
LOW
2.300
VOLUME
251.48K
TURNOVER
--
52 WEEK HIGH
13.84
52 WEEK LOW
1.750
MARKET CAP
84.79M
P/E (TTM)
-0.5938
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FPRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FPRX stock price target is 8.00 with a high estimate of 11.00 and a low estimate of 5.00.

EPS

FPRX News

More
  • Edited Transcript of FPRX earnings conference call or presentation 27-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/18 22:54
  • Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology
  • Business Wire · 03/13 14:25
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37
  • The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
  • Benzinga · 03/11 12:05

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About FPRX

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company’s pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.
More

Webull offers kinds of Five Prime Therapeutics Inc stock information, including NASDAQ:FPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FPRX stock news, and many more online research tools to help you make informed decisions.